Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

ARO-ALK7

Stage Phase 1/2Stale

Sponsor Arrowhead Pharmaceuticals

Sources

registry, as of 2026-07-08Stale

https://clinicaltrials.gov/study/NCT06937203

Protocol section, NCT06937203, last update posted 2026-07-08

Studies

NCT06937203

Registry NCT06937203

Phase Phase 1/2

Status Recruiting

Enrollment 150

Start 2025-05-09

Catalyst Primary completion. 2027-02-01Stale

Part 1 and Part 2 (optional cohort): ARO-ALK7

Part 1 and Part 2 (optional cohort): Placebo

Part:2: ARO-ALK7 + Tirzepatide

Part 2: Placebo + Tirzepatide